PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

Go online to PeerView.com/ZKC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in oncology and respiratory medicine share insights on how to best integrate novel blood-based cancer diagnostic technologies into clinical practice in order to facilitate timely diagnosis and treatment initiation.Upon completion of this activity, participants will be able to: Review the scientific principles of liquid biopsy as a tool for cancer diagnosis, including relevant biomarkers, as well as strengths and limitations compared with conventional diagnostic techniques, Describe the role and clinical implications of emerging blood-based diagnostic aids for cancer in secondary and tertiary care settings, Adapt current diagnostic workflows for cancer based on recent evidence on emerging blood-based diagnostic tests in an effort to expedite cancer discovery and subsequent treatment, Apply a patient-centered approach to the diagnosis and transition of care for patients with cancer, including educating patients on potential blood-based testing options.

Go online to PeerView.com/TWX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts in cardiovascular medicine discuss the benefits of telemedicine when screening and caring for patients with nonvalvular atrial fibrillation (NVAF). Upon completion of this activity, participants will be able to: Identify the benefits of using telemedicine and remote care services to diagnose and manage patients with NVAF, Describe ways in which telemedicine and remote care services can be used to increase patient awareness about the risks of NVAF and overcome healthcare disparities to improve healthcare delivery for patients with untreated NVAF, Operationalize best practices to design processes and procedures for a telemedicine or remote care program to manage patients with NVAF and prevent stroke, Employ telemedicine and remote care services to diagnose and manage patients with NVAF during the COVID-19 pandemic and beyond.

Go online to PeerView.com/ECU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in oncology discuss real-world applications of emerging data and innovative therapeutics, offering practical strategies for developing sound, evidence-based protocols to provide more potent and effective treatment options to patients with bladder cancer. Upon completion of this activity, participants should be better able to: Describe when and how novel therapeutic agents in advanced bladder cancer can be used over multiple lines of treatment and across patient populations, Cite the latest safety and efficacy data on newer therapies, including immune checkpoint inhibitors, targeted agents, antibody-drug conjugates and gene therapy across the spectrum of bladder cancer settings, Select novel therapeutics for the management of bladder cancer based on patient-related factors and preferences, Develop appropriate management plans that take into account unique adverse events associated with new immune-, targeted-, and antibody-, and gene therapy-based treatments for bladder cancer.

Go online to PeerView.com/HYU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in rheumatology discusses treatment with IL-17 inhibitors in nonradiographic axial spondyloarthritis. Upon completion of this activity, participants should be better able to: Recognize unmet needs in the treatment of nonradiographic axial spondyloarthritis (nr-axSpA), Discuss the rationale for IL-17 inhibition as a treatment approach to axSpA, Summarize efficacy and safety data related to IL-17 inhibitors for the treatment of nr-axSpA, Apply anti-IL-17 therapy for the treatment of nr-axSpA in accordance with current evidence and individual patient needs.

Go online to PeerView.com/BCF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. A new, expert-led MasterClass from PeerView and the Us TOO International Prostate Cancer Education & Support Network will provide guidance on individualizing treatment regimens for patients with prostate cancer and will address the latest clinical evidence and guidelines/expert consensus recommendations. The program will also offer information on relevant patient-, tumor-, and treatment-related factors, as well as how to handle patients’ specific needs and preferences. Upon completion of this activity, participants should be better able to: Review recent safety and efficacy data of emerging and available agents across the prostate cancer disease continuum (nmCRPC, mCSPC, mCRPC), including the latest evidence and expert recommendations for selection and sequencing of approved hormonal and chemotherapy options, Outline the latest clinical evidence for appropriate use of novel therapies (eg, PARP inhibitors and immunotherapy) in mCRPC, including monotherapy and combination approaches, Evaluate the latest genetic testing guidelines to better direct treatment decision-making throughout the prostate cancer disease continuum, Develop evidence-based, tailored treatment plans, including the option of clinical trial enrollment, for patients with prostate cancer, based on disease-, patient-, and treatment-specific factors.

Go online to PeerView.com/MME860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Myelofibrosis (MF) is a rare myeloproliferative neoplasm which can lead to marrow fibrosis, neo-angiogenesis, and osteosclerosis causing progressive splenomegaly with or without hepatomegaly. Currently, the only potential cure for MF is hematopoietic cell transplantation (HCT). However, the emergence and validation of JAK inhibitors has impacted treatment decisions, including the timing of HCT, and newer evidence suggests that next-generation JAK inhibitors may also play a role in challenging treatment settings defined by failure of upfront JAK inhibitor therapy. Clinicians therefore should be prepared to develop truly personalized, newer therapeutic strategies for MF management that consider all available options—from targeted agents to supportive care, as well as HCT—and address the role of JAK inhibitors in patients who are transplant candidates and determine their role before and, possibly, after transplantation. In this activity based on a recent live web broadcast, a panel of experts describes the current therapeutic landscape of MF, including JAK inhibitors and HCT. They also review evidence supporting the use of first- and second-generation JAK inhibitors and other targeted agents in MF. Upon completion of this activity, participants should be better able to: Describe modern diagnostic and prognostic models, as well as molecular and clinical features that are useful for capturing myelofibrosis (MF) presentations, including primary MF and post-PV/ET MF, Review the current therapeutic role of JAK inhibitors and allogeneic hematopoietic cell transplantation (HCT), including reduced-intensity transplant, in the management of MF, Cite recent safety and efficacy evidence supporting the use of first- and second-generation JAK inhibitors and other targeted agents in the management of MF, Integrate modern JAK inhibitor-based regimens into risk-adapted treatment plans for patients with symptomatic MF, including those who are eligible for allogeneic transplantation or as sequential options in the non-HCT setting.

Go online to PeerView.com/CAV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an immuno-oncology expert describes the benefits and limitations of available immune checkpoint inhibitors, investigational immunotherapies, and rational combinations that may expand the therapeutic landscape for various malignancies, and explains how to integrate the latest immunotherapy approaches into cancer care in the context of clinical practice or ongoing studies. Upon completion of this activity, participants should be better able to: Summarize the benefits and limitations of available immune checkpoint inhibitors and the need for novel immunotherapies and combinations to optimize outcomes for patients with cancer, Discuss investigational immunotherapies and rational combinations that may be able to expand on the current therapies or overcome immune evasion and resistance, Integrate the latest immunotherapy approaches into cancer care in the context of clinical practice or clinical trials.

Go online to PeerView.com/RZD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in ophthalmology discusses improving patient outcomes in neovascular age-related macular degeneration. Upon completion of this activity, participants should be better able to: Recognize the burden associated with conventional anti-VEGF treatment regimens for neovascular AMD, Assess the latest clinical data (eg, efficacy, safety, maximum effective dosing interval) for approved neovascular AMD treatment regimens, Apply individualized treatment plans for patients with neovascular AMD, Identify clinical strategies to assess for and manage rare adverse events associated with anti-VEGF therapies.

Go online to PeerView.com/VCJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in ophthalmology discusses evidence-based strategies for identifying and managing diabetic retinopathy (DR). Upon completion of this activity, participants should be better able to: Summarize current guidelines regarding the treatment of patients with DR, Evaluate the evidence for using currently approved intravitreal anti-VEGF therapies to prevent vision-threatening outcomes in patients with DR, Individualize treatment by incorporating current guidance and clinical trial results for anti-VEGF therapies into care for patients with DR.

Go online to PeerView.com/NBT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in COPD discusses evidence-based guidelines to diagnose and treat COPD, as well as multidisciplinary strategies to increase adherence to treatment. Upon completion of this activity, participants will be able to: Employ evidence-based guidelines to diagnose patients with chronic obstructive pulmonary disease (COPD), Create treatment plans for patients with COPD according to evidence-based guidelines to minimize exacerbation risk, preserve lung function, and improve quality of life, Discuss opportunities for members of the healthcare team to improve care for patients with COPD and minimize time constraints on primary care physicians, Apply strategies for patients to become more engaged in their care to improve adherence to treatment regimens.